Artiva Biotherapeutics Inc [ARTV] stock is trading at $2.04, up 13.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ARTV shares have gain 26.71% over the last week, with a monthly amount drifted -1.92%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on December 30, 2024, and set its price target to $20. On August 13, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $18 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Needham initiated its recommendation with a Buy and recommended $23 as its price target on August 13, 2024. Jefferies started tracking with a Buy rating for this stock on August 13, 2024, and assigned it a price target of $21. In a note dated August 13, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $23 on this stock.
Artiva Biotherapeutics Inc [ARTV] stock has fluctuated between $1.47 and $17.31 over the past year. Currently, Wall Street analysts expect the stock to reach $20.5 within the next 12 months. Artiva Biotherapeutics Inc [NASDAQ: ARTV] shares were valued at $2.04 at the most recent close of the market. An investor can expect a potential return of 904.9% based on the average ARTV price forecast.
Analyzing the ARTV fundamentals
Artiva Biotherapeutics Inc [NASDAQ:ARTV] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.67 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.85 points at the first support level, and at 1.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.15, and for the 2nd resistance point, it is at 2.26.
Ratios To Look Out For
For context, Artiva Biotherapeutics Inc’s Current Ratio is 13.93. As well, the Quick Ratio is 13.93, while the Cash Ratio is 2.49.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Jul 22 ’24 when 8.33 million shares were purchased. 10% Owner, 5AM Partners VI, LLC completed a deal on Jul 22 ’24 to buy 0.83 million shares. Meanwhile, 10% Owner venBio Global Strategic Fund I bought 0.42 million shares on Jul 22 ’24.
